Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium Respimat add-on therapy in severe persistent asthma
2005-005615-21Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tiotropium in severe asthma and asthma (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Peak FEV1 response within 3 hours post-dose at the end of the 8-week treatment period. Started Jun 2006; status: completed.
02
Drugs
tiotropium
03
Conditions
severe asthmaasthma
Beyond the preview
Go deeper on 2005-005615-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005615-21.